GLYCOSTIGMIN

This brand name is authorized in Finland.

Active ingredients

The drug GLYCOSTIGMIN contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Glycopyrronium bromide UNII `V92SO9WP2I` - GLYCOPYRROLATE
	Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways.
	Read more about Glycopyrronium
`2`	Neostigmine UNII `98IMH7M386` - NEOSTIGMINE METHYLSULFATE
	Neostigmine inhibits cholinesterase activity and prolongs and intensifies the muscarinic and nicotinic effects of acetylcholine. The anticholinesterase actions of neostigmine are reversible. It is used mainly for its action on skeletal muscle and less frequently to increase the activity of smooth muscle.
	Read more about Neostigmine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07AA51	Neostigmine, combinations	N Nervous system → N07 Other nervous system drugs → N07A Parasympathomimetics → N07AA Anticholinesterases
Discover more medicines within N07AA51

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FI	Lääkealan turvallisuus- ja kehittämiskeskus	193318

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.